Zeo ScientifiX, Inc. (ZEOX)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 3 | 6 | 6 | 5 | 5 | 5 | 7 | - |
| Operating profit | $m | -5 | -4 | ||||||
| Net profit | $m | -13 | -13 | -9 | -7 | -5 | -6 | -4 | - |
| EPS reported | $ | -0.86 | -0.58 | ||||||
| Operating cashflow per share | $ | -0.11 | -0.16 | ||||||
| Capex per share | $ | 0.00 | 0.01 | ||||||
| FCF per share | $ | -0.12 | -0.17 | ||||||
| Free cash flow | $m | -1 | -1 | ||||||
| Net debt | $m | 0 | -2 | ||||||
| Book value equity | $m | -1 | 1 | ||||||
| Book value per share | $ | -0.22 | 0.09 | ||||||
| Number of shares | m | 6.41 | 7.76 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | -8.42 | 16.84 | ||||||
| P/S LTM | x | 2.31 | 1.72 | ||||||
| P/FCF LTM | x | -16.18 | -8.88 | ||||||
| EV/EBITDA LTM | x | -2.27 | -3.25 | ||||||
| EV/Sales LTM | x | 2.33 | 1.34 | ||||||
| Earnings Yield LTM | % | -46.06% | -35.26% | ||||||
| FCF Yield | % | -6.18% | -11.26% | ||||||
| Quality | |||||||||
| ROE | % | +387.98% | +455.87% | ||||||
| ROIC | % | +5.03% | -5.11% | ||||||
| Operating margin | % | -1.04% | -59.10% | ||||||
| Gross margin | % | +82.09% | +81.52% | ||||||
| FCF/Sales | % | -14.25% | -19.32% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +12.53% | +51.23% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -2.10 | -14.06 | ||||||
| Net Debt/EBITDA | x | -0.02 | 0.47 | ||||||
| EBIT/Net interest | x | -54.96 | -54.33 | ||||||
| Net debt/market cap | % | +2.67% | +0.86% | ||||||
| Net debt/Equity | x | -0.07 | -2.59 | ||||||
| Gross debt/equity | x | -0.25 | 0.13 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Zeo ScientifiX, Inc. is a clinical-stage biopharmaceutical company specializing in developing biological therapeutics aimed at treating degenerative diseases and fostering regenerative medicine. Its flagship investigational product, Zofin, is an acellular biologic therapy sourced from perinatal materials. This candidate is currently in Phase I/II clinical trials, evaluating its efficacy for COVID-19, chronic obstructive pulmonary disease (COPD), and knee osteoarthritis. The company's portfolio also includes Patient Pure X, an autologous, blood-derived biologic technology designed to enhance the body's natural capacity to reduce cellular inflammation and promote tissue healing. Furthermore, Zeo ScientifiX develops and distributes products containing its proprietary ingredients for topical aesthetic applications. These offerings include ZEO GROW X, a professional-grade formula delivering concentrated topical exosomes to support follicular function, as well as ZEO GROW BOOST and EXO FOLLICLE FUEL. Founded in 2011, the company was formerly known as Organicell Regenerative Medicine, Inc. before rebranding to Zeo ScientifiX, Inc. in February 2024. It is headquartered in Davie, Florida.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Not enough data to calculate KvantraRank
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Zeo ScientifiX, Inc. is a clinical-stage biopharmaceutical company specializing in developing biological therapeutics aimed at treating degenerative diseases and fostering regenerative medicine. Its flagship investigational product, Zofin, is an acellular biologic therapy sourced from perinatal materials. This candidate is currently in Phase I/II clinical trials, evaluating its efficacy for COVID-19, chronic obstructive pulmonary disease (COPD), and knee osteoarthritis. The company's portfolio also includes Patient Pure X, an autologous, blood-derived biologic technology designed to enhance the body's natural capacity to reduce cellular inflammation and promote tissue healing. Furthermore, Zeo ScientifiX develops and distributes products containing its proprietary ingredients for topical aesthetic applications. These offerings include ZEO GROW X, a professional-grade formula delivering concentrated topical exosomes to support follicular function, as well as ZEO GROW BOOST and EXO FOLLICLE FUEL. Founded in 2011, the company was formerly known as Organicell Regenerative Medicine, Inc. before rebranding to Zeo ScientifiX, Inc. in February 2024. It is headquartered in Davie, Florida.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free